Biovian
Biovian (3PBIOVIAN) is a privately-held European biologics CDMO providing GMP contract development and manufacturing services for recombinant proteins, viral vectors (AAV, adenovirus), plasmid DNA, and cell therapies to biotech and pharmaceutical clients globally.
- Company typePrivate
- Founded2003
- HeadquartersTurku, Finland
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Biovian does
Biovian, operating commercially as 3PBIOVIAN, is a privately-held biologics Contract Development and Manufacturing Organization (CDMO) headquartered in Turku, Finland with a second manufacturing site in Pamplona-Noáin, Spain. Founded in 2003 and employing 101-250 staff, the company provides end-to-end GMP manufacturing services for biopharmaceutical clients spanning pre-clinical development through commercial supply. Its service portfolio covers four core modalities — recombinant proteins (via both microbial/bacterial and mammalian/CHO expression systems), viral vectors (including adeno-associated virus manufactured through its proprietary AAVion® platform and adenovirus), plasmid DNA, and cell therapies — supplemented by aseptic fill-and-finish, quality control testing, and conjugated biotherapeutics services.
The business model is a B2B fee-for-service CDMO structure, with quote-based project pricing, multi-year contracts, and direct enterprise engagement with biotech and pharmaceutical clients across Europe, the US, and Asia. The go-to-market combines direct field sales with event-driven lead generation at major industry conferences (Nordic Life Science Days, BioProcess International, BIOSPAIN, CPHI) and content-led demand generation on its website and LinkedIn presence. The company received institutional investment from EQT in 2018 and rebranded to the unified 3PBIOVIAN identity in 2024. Legal entity is 3P BIOPHARMACEUTICALS, S.L.U., a Spanish private limited company (Sociedad Limitada Unipersonal). Revenue, ownership composition, and customer-level data are not publicly disclosed.
Biovian firmographics
Firmographics- Name
- Biovian
- Legal name
- 3P BIOPHARMACEUTICALS, S.L.U.
- Website
- https://biovian.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Biovian (3PBIOVIAN) is a privately-held European biologics CDMO providing GMP contract development and manufacturing services for recombinant proteins, viral vectors (AAV, adenovirus), plasmid DNA, and cell therapies to biotech and pharmaceutical clients globally.
- Ownership category
- akta.pro rank
Biovian industry classification
Industry- Product category
- Biologics Contract Development and Manufacturing
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB)
- akta.pro secondary industries
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)
Keywords
Where Biovian is headquartered
LocationHeadquarters
- HQ city
- Turku
- HQ country
- Finland
- HQ region
- Europe
Offices2 records
Markets served
Biovian business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales
Revenue model
- Contract Manufacturing Services: Biovian generates revenue through contract development and manufacturing services. As a CDMO, they provide fee-for-service manufacturing across the product lifecycle, from pre-clinical and clinical development through commercial manufacturing. Revenue is generated through project-based contracts, long-term manufacturing agreements, and development service contracts with biotech and pharmaceutical clients requiring GMP-compliant production of biologics, viral vectors, plasmid DNA, and cell therapies.
- Development and Testing Services: Additional revenue streams include process development services, analytical testing and QC services, aseptic fill and finish services, and conjugated biotherapeutics development. These specialized services support the core manufacturing business and provide integrated solutions for clients throughout the drug development journey.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based pricing for CDMO services |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Biovian product offering
Product offeringCore offering
Biovian (3PBIOVIAN) is a Contract Development and Manufacturing Organization (CDMO) providing GMP-compliant biologics manufacturing services from early-stage development through commercial supply. The company offers integrated services across recombinant proteins (microbial and mammalian), viral vectors (AAV, adenovirus), plasmid DNA, and cell therapies, supported by aseptic fill and finish, QC testing, and conjugated biotherapeutics capabilities. Operations are run from two manufacturing sites in Turku, Finland and Pamplona-Noáin, Spain, serving biotech and pharmaceutical clients globally.
Product overview
3PBIOVIAN is a global Contract Development and Manufacturing Organization (CDMO) offering integrated biologics manufacturing services from early-stage development through commercialization. The portfolio spans four core service areas: Proteins (microbial and mammalian expression systems), Viral Vectors (including AAV via the proprietary AAVion® Platform, and adenovirus), Plasmid DNA, and Cell Therapies. These core services are supported by additional capabilities including Aseptic Fill & Finish, QC Services, and Conjugated Biotherapeutics. The company provides end-to-end development and manufacturing for both Drug Substances and Drug Products, serving clients across preclinical, clinical (Phase I-III), and commercial phases. Manufacturing facilities are located in Pamplona-Noáin, Spain and Turku, Finland.
Differentiator
Problem solved
Functional benefit
Brands
- AAVion® Platform: Proprietary AAV manufacturing platform for gene therapy vector production.
Products and services
- Recombinant Protein Manufacturing GMP-compliant recombinant protein manufacturing services covering microbial (bacterial) and mammalian (CHO) expression systems for pre-clinical, clinical (Phase I-III), and commercial production. Intended for biotech and pharmaceutical companies developing protein-based biologics.
- Viral Vector Manufacturing GMP viral vector manufacturing services for gene therapy and vaccine development, including adeno-associated virus (AAV) and adenovirus production for pre-clinical through commercial supply. Target customers are gene therapy developers and vaccine developers in biotech and pharma.
- AAVion® AAV Manufacturing Platform Proprietary AAV (Adeno-Associated Virus) manufacturing platform enabling flexible and efficient viral vector production for gene therapy applications. Used as the in-house platform for Biovian's AAV manufacturing service line.
- Plasmid DNA Manufacturing GMP plasmid DNA CDMO services for pre-clinical, clinical, and commercial production following the same GMP standards applied to drug substance and drug product manufacturing. Targeted at developers of gene therapies, DNA vaccines, and cell therapies.
- Cell Therapy Manufacturing Cell and gene therapy services supporting development, manufacturing, and commercialization of cell-based therapies for biotech and pharmaceutical clients.
- Aseptic Fill & Finish Integrated aseptic fill and finish services for drug products including formulation, terminal sterilization or aseptic processing, visual inspection, in-house sterility testing, labeling, packaging, and Qualified Person (QP) certified release.
- Quality Control (QC) Services Quality control testing services supporting biopharmaceutical manufacturing compliance, including analytical and release testing for drug substance and drug product.
- Conjugated Biotherapeutics Manufacturing Manufacturing services for conjugated biotherapeutics combining biologic components with targeting agents, such as antibody-drug conjugates and related modalities.
Companies that use Biovian
Customer profileSegments2 records
Ideal customer profiles2 records
Biovian technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Biovian partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights5 records
Biovian competitors and assessment
Company assessmentBroad incumbents
- Lonza Group: Global Tier-1 CDMO with massive biologics, viral vector, and cell therapy capacity. Competes head-to-head with Biovian for gene therapy and mammalian protein programs but at vastly larger scale.
- Samsung Biologics: Large-scale Korean CDMO focused on mammalian biologics manufacturing with rapidly expanding gene therapy services. Represents the scale competition that Biovian faces in winning commercial-stage programs.
- Thermo Fisher Scientific (Patheon): Global pharma services platform with biologics CDMO, viral vector, and fill-finish capabilities. Competes with Biovian across multiple modalities through its Patheon and Brammer Bio heritage.
- WuXi Biologics: China-based global biologics CDMO with end-to-end capabilities from cell line development to commercial manufacturing. Direct competitor for biotech outsourcing decisions, including plasmid and viral vector services.
- Catalent: Global CDMO with biologics, viral vector, and cell therapy capabilities alongside its dominant fill-finish business. Competes with Biovian for biologics manufacturing and integrated DS-to-DP programs.
Direct peers
- AGC Biologics: Mid-to-large global CDMO offering microbial and mammalian protein, viral vector, and cell therapy services. One of the closest direct peers to Biovian by modality mix and target client base.
- Rentschler Biologics: European-based CDMO specializing in mammalian cell culture recombinant proteins and gene therapy manufacturing. Closely comparable mid-sized European CDMO competing for the same biotech clients.
- Vibalogics: Specialist viral vector CDMO focused on late-stage clinical and commercial GMP manufacturing of oncolytic viruses and viral vaccines. Highly comparable to Biovian's viral vector service line.
- Cobra Biologics (Charles River Laboratories): European CDMO providing viral vector and plasmid DNA manufacturing services for gene therapy and vaccine clients, now part of Charles River. Closely aligned with Biovian's plasmid and viral vector CDMO offering.
- Yposkesi: French gene therapy CDMO producing AAV and lentiviral vectors for clinical and commercial supply. Comparable European specialty viral vector CDMO competing in the same gene therapy client segment as Biovian.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Biovian social profiles
Digital presenceBiovian financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biovian leadership team
Management profileNumber of profiles
Profiles2 records
Biovian funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biovian M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biovian
What does Biovian do?
Biovian (3PBIOVIAN) is a Contract Development and Manufacturing Organization (CDMO) providing GMP-compliant biologics manufacturing services from early-stage development through commercial supply. The company offers integrated services across recombinant proteins (microbial and mammalian), viral vectors (AAV, adenovirus), plasmid DNA, and cell therapies, supported by aseptic fill and finish, QC testing, and conjugated biotherapeutics capabilities. Operations are run from two manufacturing sites in Turku, Finland and Pamplona-Noáin, Spain, serving biotech and pharmaceutical clients globally.
Is Biovian a public or private company?
Biovian is a private company. It is classified as private equity controlled and is currently operating.
When was Biovian founded?
Biovian was founded in 2003. It employs 101 to 250 people.
Where is Biovian based?
Biovian is headquartered in Turku, Finland, in the Europe region.
How does Biovian make money?
Two revenue lines are on record. Contract Manufacturing Services are the primary driver. The others are development and Testing Services.
Who are Biovian's main competitors?
Broad incumbents on record are Lonza Group, Samsung Biologics, Thermo Fisher Scientific (Patheon), WuXi Biologics and Catalent. Direct peers are AGC Biologics, Rentschler Biologics, Vibalogics, Cobra Biologics (Charles River Laboratories) and Yposkesi.
Does Biovian have an API?
No public API is recorded for Biovian.
What industry is Biovian in?
Biovian's product category is Biologics Contract Development and Manufacturing. Its primary akta.pro industry code is HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing), with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 325414 and its SIC code is 2836.